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Association of body composition with odds
of breast cancer by molecular subtype:
analysis of the Mechanisms for Established
and Novel Risk Factors for Breast Cancer in
Nigerian Women (MEND) study
Tomi Akinyemiju1,2,3*, Kelley Jones1, Anjali Gupta1,4, Taofik Oyekunle1, Veeral Saraiya5, April Deveaux1,
Omolola Salako6, Allison Hall7, Olusegun Alatise8, Gabriel Ogun9, Adewale Adeniyi10, Omobolaji Ayandipo9,
Thomas Olajide6, Olalekan Olasehinde8, Olukayode Arowolo8, Adewale Adisa8, Oludolapo Afuwape9,
Aralola Olusanya9, Aderemi Adegoke11, Trygve O. Tollefsbol12, Donna Arnett13, H3 Africa Kidney Research Network
14 and Adetola Daramola6
Abstract
Background: The association between obesity and breast cancer (BC) has been extensively studied among US,
European and Asian study populations, with often conflicting evidence. However, despite the increasing prevalence
of obesity and associated conditions in Africa, the continent with the highest age-standardized BC mortality rate
globally, few studies have evaluated this association, and none has examined in relation to molecular subtypes
among African women. The current analysis examines the association between body composition, defined by body
mass index (BMI), height, and weight, and BC by molecular subtype among African women.
Methods: We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association between
measures of body composition and BC and molecular subtypes among 419 histologically confirmed cases of BC
and 286 healthy controls from the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Women
of Nigerian Descent (MEND) case-control study.
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Results: Higher BMI (aOR: 0.79; 95% CI: 0.67, 0.95) and weight (aOR: 0.83; 95% CI: 0.69, 0.98) were associated with
reduced odds of BC in adjusted models, while height was associated with non-statistically significant increased
odds of BC (aOR: 1.07, 95% CI: 0.90, 1.28). In pre/peri-menopausal, but not post-menopausal women, both higher
BMI and weight were significantly associated with reduced odds of BC. Further, higher BMI was associated with
reduced odds of Luminal A, Luminal B, and HER2-enriched BC among pre/peri-menopausal women, and reduced
odds of triple-negative BC among post-menopausal women.
Conclusions: Higher BMI and weight were associated with reduced odds of BC overall and by molecular subtype
among West African women. Larger studies of women of African descent are needed to definitively characterize
these associations and inform cancer prevention strategies.
Keywords: Body composition, BMI, Breast cancer, Nigeria, Molecular subtype, Hormone receptor
Background
Breast cancer (BC) poses a significant global challenge,
with an estimated 2.1 million new cases and over 0.6
million deaths occurring in 2018 [1]. The African con-
tinent has the highest age-standardized BC mortality rate
globally, with Nigeria, the most populous African nation,
experiencing the highest rate within the continent [2]. In
addition, the past few decades have been characterized
by rapid increases in BC incidence rates among African
women [3]. This increase is thought to be partly attrib-
utable to an epidemiological transition—a trend charac-
terized by a decline in infectious diseases and an
increase in non-communicable diseases, including obes-
ity, obesity-associated conditions, as well as cancer [4,
5]. Women of African descent are also more likely to ex-
perience disproportionately high rates of aggressive BC
tumors with poorer prognosis [6–8]. Specifically, women
of African descent, including African-American women
in the United States [9] and Nigerian women, are more
likely to be diagnosed with BC over-represented by
the triple-negative (TN) subtypes, characterized by estro-
gen (ER), progesterone (PR), and human epidermal
growth factor-2 (HER2) receptor negativity [7, 8].
Non-communicable disease risk factors, such as high
body mass index (BMI), have been shown to influence
BC risk. Several studies have found that higher BMI, an
indicator of excess adiposity, is associated with increased
risk of post-menopausal BC, but reduced risk of pre-
menopausal BC [10, 11]. This association has been ob-
served among diverse populations, including European
[12], Latin American [13], and Asian [14] women. How-
ever, the few studies in Nigeria, where obesity rates are
rapidly increasing [15], are mixed. Two studies have
noted no significant associations between BMI and BC
risk [16, 17], while studies assessing other measures of
excess adiposity, such as waist circumference and waist-
to-hip ratio, observed an association with increased risk
of BC in Nigerian women [17, 18]. These measures of
excess adiposity have been associated with metabolic
dysregulation, including insulin resistance and
hyperlipidemia [19], which have separately been shown
to increase BC risk [20]. Additionally, studies consider-
ing body height have found a positive association be-
tween height and BC risk [21, 22], including two studies
among Nigerian women [16, 23]. Molecular BC subtype
has been shown to modify the association between ex-
cess adiposity and BC risk. Obese women were found to
have a higher risk of TN and Luminal A BC than
normal-weight women, whereas normal-weight women
were more likely to present with HER2+ BC in a popula-
tion from the United States [24]. Another United States
study found that elevated waist-to-hip ratio was associ-
ated with increased risk of Luminal A BC among post-
menopausal women, and increased risk of basal-like
(TN) BC in both pre- and post-menopausal women [25].
However, no study to date has examined the link be-
tween BMI and BC molecular subtypes in West African
women.
Improved understanding of the impact of obesity on
BC and molecular subtypes in West African women will
add to the growing literature that can help inform locally
relevant BC prevention strategies and contribute to en-
hancing existing risk prediction and prognostic models.
Findings will also contribute to improved understanding
of the biological mechanisms underlying aggressive
tumor subtypes in women of African descent. The pur-
pose of the current study was to evaluate the association
between BMI, height, and weight with odds of BC




The Mechanisms for Established and Novel Risk Factors
for Breast Cancer in Women of Nigerian Descent
(MEND) study has been previously described in detail
[26]. Briefly, newly diagnosed BC patients from four ter-
tiary hospitals in southwestern Nigeria were recruited
into the research study. A trained research nurse at each
site introduced the study and explained study
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requirements in detail to potential participants during
clinical visits, and interested participants were assessed
for eligibility. Exclusion criteria included other medical
conditions that could interfere with participation in the
study, mental impairment, or not being able to commu-
nicate in English themselves or through a family mem-
ber to complete the survey. Written and verbal informed
consent was obtained from all study participants. A
comprehensive study questionnaire was administered to
obtain information on sociodemographic characteristics,
reproductive history, and self and family history of can-
cer. Anthropometric measurements were obtained by
the research nurse, followed by blood sample collection,
and tumor and adjacent normal tissue biopsy sample
collection. All biospecimen were collected prior to any
chemotherapy or surgical treatment. Tissue samples
were processed at the clinic and stored in − 80 °C
freezers until shipment to the United States for further
analysis. Participants received a N500 telephone recharge
card (approximately US $1.50) as well as supplies needed
for their clinical biopsy (biopsy needle and ancillary
items). Data on healthy controls without BC were ob-
tained from the Human Heredity and Health Africa
(H3A) Chronic Kidney Disease (CKD) case-control
study; methodology for the H3A CKD study has been
described elsewhere [27]. Briefly, H3A recruitment oc-
curred between 2015 and 2017, overlapping with case
recruitment and included the recruitment of healthy,
community-based adult women in southwestern Nigeria
and Ghana. Extensive socio-demographic, clinical, family
history and behavioral risk factor data was collected
from all control participants; those with history of can-
cer or missing data on cancer history were excluded
from analysis. Overall, 419 BC cases and 286 healthy
controls were included in the current analysis (Fig. 1).
All study procedures were approved by Duke University
and the participating hospitals’ Institutional Review
Boards.
Breast cancer cases and subtyping
BC diagnosis was confirmed in one of two ways: 1) path-
ology reports based on clinical tumor biopsy samples
from the diagnosing hospital in Nigeria and reviewed by
a trained pathologist, or 2) research tumor biopsy sam-
ples collected at recruitment (same time as clinical bi-
opsy) and shipped to the United States for review by a
pathologist. Participants were considered a confirmed
cancer case if either report indicated a cancer diagnosis.
Confirmed BC tumor samples were subjected to immu-
nohistochemistry (IHC) either at the diagnosing hospital
Fig. 1 CONSORT diagram for MEND body composition analysis
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in Nigeria following standard protocol, or at the Duke
University BioRepository and Precision Pathology Cen-
ter. When both Nigeria and Duke IHC results were
available, the Duke typing was used because it consti-
tuted the majority of IHC data on cases. Estrogen recep-
tor and progesterone receptor status were scored using
the Allred method [28, 29]. The proportion of nuclear
positivity was scored as 0 (0%), 1 (< 1%), 2 (1–10%), 3
(11–33%), 4 (34–66%) or 5 (67–100%); intensity of the
staining was scored as 0 (none), 1 (mild), 2 (moderate),
or 3 (strong). These two scores were summed into posi-
tive (3–8) or negative (0–2). HER2 was scored as nega-
tive (scores 0, 1), equivocal (score = 2), positive (score =
3) [30]. Cancer subtype was then classified as Luminal A
(ER+ and/or PR+ / HER2-), Luminal B (ER+ and/or PR+
/ HER2+), TN (ER−/PR−/HER2-), or HER2 (ER−/PR
−/HER2+). In total, 169 cases had available data on ER/
PR/HER2 status for molecular subtype classification.
Measures
Anthropometric measurements for cases and controls
were collected by trained research staff at enrollment,
and included height, weight, and blood pressure. BMI
was calculated from height and weight as kg/m2. BMI,
height, and weight were categorized into quartiles as
well as continuous standardized variables by subtracting
the sample mean and dividing by the sample standard
deviation (SD). Quartiles were used rather than World
Health Organization BMI categories (< 18.5 kg/m2
underweight, 18.5 - < 25 normal weight, 25 - < 30 over-
weight, and 30+ obese) because it has been documented
that these categories may not accurately capture risk in
populations of African descent [31]. Reproductive and
clinical history were self-reported by participants, and
study covariates included age at menarche, parity, gra-
vidity, menopausal status, and prior hypertension diag-
nosis. Participants also self-reported whether they had a
history of other types of cancer; those with a positive
history of cancer (< 1% of cases and controls) or missing
personal cancer history data (15% of controls) were ex-
cluded from the analysis. Missing data for all measures
were tabulated by case/control status. Variables with <
10% missing for both cases and controls were replaced
with the median or modal value of the cases or controls,
respectively, while variables with > 10% missing were not
imputed.
Analytical approach
Descriptive statistics of proportions and frequencies for
categorical variables and means (SD) or medians (first
quartile, third quartile) for continuous variables were
used to characterize the sample by case/control status
and BMI quartile. Differences in characteristics were
tested using χ2 tests for categorical variables and
Wilcoxon rank-sum or Kruskal-Wallis nonparametric
tests for continuous variables. The distribution of BMI
was evaluated by case/control status and stratified by
menopausal status and age group, respectively. The asso-
ciations between body composition measures (BMI,
height, and weight) and BC were tested using logistic re-
gression models. Each body composition measure was
assessed separately in a series of models: unadjusted, ad-
justed for age only, and adjusted for age, age at menar-
che, number of pregnancies, number of births,
menopausal status, and prior hypertension diagnosis. A
final model adjusted for BMI, height, and weight simul-
taneously in addition to all previous covariates. The pri-
mary models assessed quartiles as a categorical variable,
with the lowest quartile set as the reference group. To
test for trend across quartiles, the main exposure was
analyzed as a continuous variable [1–4]. Finally, the
standardized values for BMI, height, and weight were ex-
amined to determine the association per unit standard
deviation (SD) increase in the measure with the odds of
being a cancer case. These models were repeated with
stratification for menopausal status. The subset of cases
with molecular subtyping was analyzed using multi-
nomial logistic regression models, specifying control sta-
tus as the outcome reference group. The previous
models were repeated to assess the odds of Luminal A,
Luminal B, TN, or HER2 cancer subtypes. We assessed
whether H3A control participants recruited from Nigeria
and Ghana were significantly different in relation to key
body composition measures; there were no significant
difference between the groups, and in sensitivity analysis
examining the analytical models using Nigerian controls
only, results from the overall analysis were consistent,
therefore analysis with the entire cohort of controls is
presented. SAS v9.4 (SAS Institute, Cary, NC) was used
for all analyses and significance was set at α = 0.05.
Results
A total of 419 BC cases and 286 healthy controls were
included in the analysis (Fig. 1). Median age at diagnosis
or enrollment (48 years vs. 47 years), median age at me-
narche (15 years vs. 15 years), number of pregnancies (5
vs. 4) and number of births (4 vs. 4) was similar among
cases and controls (Table 1). However, cases were less
likely to report any prior use of hormone replacement
therapy compared with controls. Approximately half
(54%) of cases and 60% of controls were overweight or
obese, and controls were more likely to report a prior
diagnosis of diabetes or hypertension. Among cases, the
most common subtype was triple-negative (31%), and
38% of cases were diagnosed at advanced grade (grade
3). Across BMI quartiles (Table 2), those in the highest
quartile were older (p < 0.001), more likely to have a
prior diagnosis of hypertension (p < 0.001), report ever
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Age (years)a 48.0 (42.0, 58.0) 47.0 (40.0, 58.0)
Clinical characteristics
BMI category
Underweight (< 18.5) 21 (5.0%) 8 (2.8%)
Normal weight (18.5 - < 25) 172 (41.1%) 106 (37.1%)
Overweight (25 - < 30) 136 (32.5%) 94 (32.9%)
Obese (30+) 90 (21.5%) 78 (27.3%)
BMI quartile
≤ 22.5 117 (27.9%) 60 (21.0%)
> 22.5 - ≤25.6 110 (26.3%) 71 (24.8%)
> 25.6 - ≤29.8 99 (23.6%) 75 (26.2%)
> 29.8 93 (22.2%) 80 (28.0%)
Height, cm a 160.0 (156.0, 164.1) 159.7 (155.0, 163.5)
Weight, kg a 64.9 (55.3, 75.8) 66.0 (58.0, 78.0)
High blood pressure at enrollment 134 (32.0%) 95 (33.2%)
Systolic BP a 126.0 (114.3, 142.3) 128.5 (115.3, 144.0)
Diastolic BP a 80.0 (70.7, 88.7) 77.0 (70.0, 87.7)
Prior diabetes diagnosis
Yes 6 (1.4) 43 (15.0)
No 411 (98.1) 190 (66.4)
Missing 2 (0.5) 53 (18.5)
Prior hypertension diagnosis 82 (19.6%) 134 (46.9%)
Reproductive history
Age at menarche a 15.0 (14.0, 16.0) 15.0 (14.0, 17.0)
Ever pregnant 399 (95.2%) 269 (94.1%)
Number of pregnancies a,b 5.0 (3.0, 6.0) 4.0 (3.0, 6.0)
Number of births a,b 4.0 (3.0, 5.0) 4.0 (2.0, 5.0)
Menopausal status
Pre- or peri-menopause 207 (49.4%) 133 (46.5%)
Post-menopause 212 (50.6%) 153 (53.5%)
Ever used HRT
Yes 3 (0.7) 41 (14.3)
No 416 (99.3) 189 (66.1)
Missing 0 (0.0) 56 (19.6)
Cancer type (n = 169) n/ac
Luminal A 46 (27.2%)
Luminal B 34 (20.1%)
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Prior Mammography Screenings 78 (18.6%) n/ad
Any Family History of Cancer 21 (5.0%) n/ad
aMedian, (Q1, Q3)
bAmong those who were ever pregnant
cCancer variables are not applicable to control participants
dUnavailable for control participants
Table 2 Clinical and reproductive characteristics by BMI quartile among breast cancer cases and controls




BMI > 22.5 - ≤ 25.6
N = 181
3rd quartile:







Case 117 (66.1%) 110 (60.8%) 99 (56.9%) 93 (53.8%)
Control 60 (33.9%) 71 (39.2%) 75 (43.1%) 80 (46.2%)
Demographics
Age (years)a 46.0 (37.0, 55.0) 48.0 (40.0, 58.0) 47.5 (41.0, 56.0) 52.0 (44.0, 59.0) < .001
Clinical characteristics
Height, cm a 161.0 (156.0, 164.5) 160.0 (156.0, 164.0) 160.0 (155.0, 163.8) 160.0 (156.0, 164.1) .69
Weight, kg a 52.0 (48.5, 55.0) 62.0 (58.0, 64.9) 70.9 (66.0, 74.8) 85.9 (80.0, 94.0) < .001
High blood pressure at enrollment 32 (18.1) 68 (37.6) 65 (37.4) 64 (37.0) < .001
Systolic BP a 121.7 (109.3, 132.0) 127.0 (114.7, 145.7) 129.0 (116.7, 147.7) 132.0 (119.7, 148.7) < .001
Diastolic BP a 76.0 (66.7, 84.0) 78.3 (68.7, 89.3) 79.2 (72.3, 88.3) 80.3 (74.7, 89.7) < .001
Prior diabetes diagnosis .21
Yes 7 (4.0%) 15 (8.3%) 11 (6.3%) 16 (9.3%)
No 159 (89.8%) 156 (86.2%) 143 (82.2%) 143 (82.7%)
Missing 11 (6.2%) 10 (5.5%) 20 (11.5%) 14 (8.1%)
Prior hypertension diagnosis 32 (21.6%) 41 (28.5%) 55 (37.2%) 65 (48.1%) < .001
Reproductive history
Age at menarche a 15.0 (14.0, 16.0) 15.0 (14.0, 16.0) 15.0 (14.0, 16.0) 15.0 (14.0, 17.0) .54
Ever pregnant 161 (91.0%) 170 (93.9) 166 (95.4) 171 (98.8) .01
Number of pregnancies a,b 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 5.0 (4.0, 6.0) .15
Number of births a,b 3.0 (2.0, 5.0) 4.0 (3.0, 5.0) 4.0 (2.0, 5.0) 4.0 (3.0, 5.0) .13
Menopausal status .06
Pre- or peri-menopause 97 (54.8%) 87 (48.1%) 86 (49.4%) 70 (40.5%)
Post-menopause 80 (45.2%) 94 (51.9%) 88 (50.6%) 103 (59.5%)
Ever used HRT .009
Yes 4 (2.3%) 10 (5.5%) 11 (6.3%) 19 (11.0%)
No 159 (89.8%) 153 (84.5%) 152 (87.4%) 141 (81.5%)
Missing 14 (7.9%) 18 (9.9%) 11 (6.3%) 13 (7.5%)
Where applicable, missing values were not used to generate the p-value
aMedian, (Q1, Q3)
bAmong those who were ever pregnant
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use of HRT (p = 0.009) and be ever pregnant (p = 0.01).
Furthermore, the distribution of BMI by case/control
status stratified by menopausal status and age group
(Fig. 2) indicated that the proportion of cases compared
to controls in the lowest BMI quartile was higher across
categories of menopausal status and age.
In multivariable regression models (Table 3), BMI in
the highest versus lowest quartile (BMI > 29.8 kg/m2 vs.
< 22.5 kg/m2) was associated with reduced odds of BC in
adjusted models (aOR: 0.56; 95% CI: 0.33, 0.92; p-trend:
0.02). However, after additionally adjusting for height
and weight, the estimate was no longer statistically sig-
nificant (aOR: 0.32, 95% CI: 0.10, 1.09; p-trend 0.06).
Each SD increase in BMI was significantly associated
with 21% reduced odds of BC (aOR: 0.79; 95% CI: 0.67,
0.95) in adjusted models but was no longer significant in
models additionally adjusting for height and weight
(aOR: 0.75, 95% CI: 0.15, 3.72). Weight (kg) in the high-
est quartile was associated with 37% reduced odds of BC
(aOR: 0.63, 95% CI: 0.38, 1.04) in adjusted models, how-
ever this was not statistically significant, although each
SD increase in weight was associated with significantly
reduced odds of BC (aOR: 0.83; 95% CI: 0.69, 0.98).
Increased height was not significantly associated with
odds of BC in fully adjusted models or in weight and
height adjusted models. In sub-group analyses stratified
by menopausal status, BMI and weight were significantly
associated with reduced odds of BC only among pre/
peri-menopausal women (Fig. 3).
In multinomial logistic regression models evaluating
BC molecular subtypes compared with controls (Table 4),
highest versus lowest quartiles of BMI was associated
with reduced but not statistically significant odds of each
BC subtype, although the association of each SD in-
crease in BMI with reduced odds of Luminal B subtype
was statistically significant (aOR: 0.63; 95% CI: 0.42,
0.95). When we stratified by menopausal status, each
unit SD increase in BMI was significantly associated with
reduced odds of Luminal A (aOR 0.59; 95% CI: 0.35,
0.99), Luminal B (aOR: 0.48; 95% CI: 0.26, 0.90), and
HER2-enriched (aOR: 0.49; 95% CI: 0.27, 0.90) BC among
pre/peri-menopausal women, and reduced odds of
TNBC (aOR: 0.55; 95% CI: 0.32, 0.95) among post-
menopausal women. Height in the highest quartile was
associated with 78% reduced odds of HER2-enriched BC
(aOR: 0.22; 95% CI: 0.06, 0.83). Additionally, each unit
Fig. 2 BMI quartile by case/control status and clinical factors. a Distribution of BMI quartiles by case/control status among pre/peri-menopausal
participants. b Distribution of BMI quartiles by case/control status among post-menopausal participants. c Distribution of BMI quartiles by case/
control status among participants younger than 45 years old. d Distribution of BMI quartiles by case/control status among participants aged 45–
59 years old. e Distribution of BMI quartiles by case/control status among participants 60 years or older
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≤ 22.5 Ref. Ref. Ref. Ref.
> 22.5 - ≤25.6 0.79 (0.52, 1.22) 0.76 (0.49, 1.18) 0.73 (0.44, 1.22) 0.60 (0.31, 1.19)
> 25.6 - ≤29.8 0.68 (0.44, 1.04) 0.65 (0.42, 1.01) 0.63 (0.38, 1.04) 0.38 (0.15, 0.95)
> 29.8 0.60 (0.39, 0.92) 0.56 (0.36, 0.86) 0.56 (0.33, 0.92) 0.32 (0.10, 1.09)
P-trend .01 .01 .02 .06
aOR (95% CI) per unit SD 0.81 (0.70, 0.94) 0.79 (0.68, 0.93) 0.79 (0.67, 0.95) 0.75 (0.15, 3.72)
Height (cm) quartile
≤ 156.0 Ref. Ref. Ref. Ref.
> 156.0 - ≤160.0 1.05 (0.67, 1.64) 1.07 (0.68, 1.68) 1.05 (0.62, 1.76) 0.90 (0.51, 1.57)
> 160.0 - ≤164.0 1.41 (0.94, 2.10) 1.45 (0.97, 2.16) 1.29 (0.81, 2.05) 1.12 (0.66, 1.90)
> 164.0 1.22 (0.81, 1.84) 1.27 (0.84, 1.91) 1.08 (0.67, 1.73) 0.87 (0.48, 1.60)
P-trend .17 .13 .55 .85
aOR (95% CI) per unit SD 1.15 (0.99, 1.34) 1.16 (1.00, 1.36) 1.07 (0.90, 1.28) 1.05 (0.56, 1.96)
Weight (kg) quartile
≤ 56.7 Ref. Ref. Ref. Ref.
> 56.7 - ≤65.0 0.85 (0.56, 1.31) 0.84 (0.54, 1.28) 0.75 (0.46, 1.24) 1.09 (0.55, 2.15)
> 65.0 - ≤77.0 0.89 (0.58, 1.37) 0.87 (0.56, 1.34) 0.93 (0.56, 1.57) 2.04 (0.78, 5.29)
> 77.0 0.74 (0.48, 1.14) 0.71 (0.46, 1.10) 0.63 (0.38, 1.04) 1.70 (0.48, 5.98)
P-trend .22 .16 .14 .31
aOR (95% CI) per unit SD 0.86 (0.74, 1.00) 0.85 (0.73, 0.99) 0.83 (0.69, 0.98) 1.06 (0.20, 5.75)
P-trend based on continuous predictors; aOR per unit SD modeled as a one-unit increase in standard deviation of the variable from its mean-centered value
Bolded values indicate significance at p < .05
Abbreviations: OR odds ratio, CI confidence interval, aOR adjusted odds ratio, SD standard deviation
Logistic regression models predicted odds of breast cancer. aModel 1, unadjusted; bModel 2, adjusted for age; cModel 3, additionally adjusted for clinical and
reproductive characteristics: age at menarche, number of pregnancies, number of births, menopausal status, and prior hypertension diagnosis; dModel 4,
additionally adjusted for all body composition measures: BMI, height, and weight
Fig. 3 Associations between body composition and breast cancer by menopausal status. Logistic regression models predicting odds of breast
cancer. Adjusted for age, age at menarche, number of pregnancies, number of births, and prior hypertension diagnosis
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SD increase in weight was significantly associated with
55% reduced odds of HER2-enriched BC (aOR: 0.45;
95% CI: 0.24, 0.84) only among pre/per-menopausal
women.
Discussion
In the first contemporary cohort of newly diagnosed Af-
rican BC cases and healthy controls, increasing BMI and
weight were significantly associated with reduced odds
of BC overall, but no statistically significant association
was noted with respect to height. Similar associations
were observed among both pre/peri-menopausal and
post-menopausal women, but only reached statistical
significance among pre/peri-menopausal women. In our
analysis of BC subtypes, higher BMI was significantly as-
sociated with reduced odds of Luminal A, Luminal B,
and HER2-enriched BC among pre/peri-menopausal
women, and reduced odds of TNBC among post-
menopausal women.
Previous studies have evaluated the association be-
tween measures of body composition and BC in various
patient populations, with results suggesting a positive as-
sociation of BMI with BC risk among post-menopausal
women, and inverse association among pre-menopausal
women [10–14]. This is consistent with our findings of
significant inverse associations with BMI and weight for
Table 4 Associations between body composition measures and breast cancer subtype









≤ 22.5 Ref Ref Ref Ref
22.5–25.5 0.55 (0.22, 1.41) 0.94 (0.36, 2.50) 0.41 (0.16, 1.06) 0.97 (0.34, 2.76)
25.6–29.8 0.33 (0.12, 0.90) 0.63 (0.22, 1.76) 0.47 (0.19, 1.14) 0.70 (0.24, 2.07)
> 29.8 0.51 (0.21, 1.24) 0.35 (0.11, 1.13) 0.48 (0.20, 1.13) 0.68 (0.23, 1.97)
P-trend 0.10 0.06 0.13 .38
aOR (95% CI) per unit SD 0.82 (0.59, 1.16) 0.63 (0.42, 0.95) 0.81 (0.58, 1.12) 0.74 (0.50, 1.09)
Pre/peri-menopausal 0.59 (0.35, 0.99) 0.48 (0.26, 0.90) 0.89 (0.56, 1.42) 0.49 (0.27, 0.90)
Post-menopausal 1.03 (0.64, 1.68) 0.66 (0.36, 1.21) 0.55 (0.32, 0.95) 1.10 (0.61, 1.98)
Height (cm) quartile (all)
≤ 156.0 Ref Ref Ref Ref
> 156.0 - ≤160.0 0.88 (0.29, 2.68) 0.76 (0.24, 2.41) 1.33 (0.53, 3.36) 0.83 (0.31, 2.22)
> 160.0 - ≤164.0 1.42 (0.58, 3.50) 0.80 (0.29, 2.18) 1.02 (0.43, 2.41) 0.66 (0.27, 1.65)
> 164.0 1.39 (0.55, 3.51) 1.18 (0.46, 3.03) 1.01 (0.41, 2.45) 0.22 (0.06, 0.83)
P-trend .35 .74 .89 .03
aOR (95% CI) per unit SD 1.20 (0.86, 1.67) 1.09 (0.76, 1.57) 1.05 (0.77, 1.44) 0.74 (0.51, 1.07)
Pre/peri-menopausal 1.23 (0.78, 1.93) 1.39 (0.85, 2.27) 0.77 (0.48, 1.23) 0.72 (0.44, 1.16)
Post-menopausal 1.19 (0.71, 2.01) 0.78 (0.46, 1.33) 1.43 (0.89, 2.28) 0.78 (0.42, 1.44)
Weight (kg) quartile (all)
≤ 56.7 Ref Ref Ref Ref
> 56.7 - ≤65.0 0.46 (0.16, 1.29) 2.14 (0.76, 6.03) 0.52 (0.21, 1.30) 0.84 (0.32, 2.22)
> 65.0 - ≤77.0 0.65 (0.25, 1.73) 1.32 (0.42, 4.18) 0.77 (0.32, 1.88) 0.48 (0.15, 1.54)
> 77.0 0.73 (0.30, 1.75) 0.46 (0.12, 1.77) 0.54 (0.23, 1.30) 0.52 (0.19, 1.44)
P-trend .67 .14 .29 .15
aOR (95% CI) per unit SD 0.91 (0.65, 1.27) 0.68 (0.45, 1.01) 0.83 (0.60, 1.14) 0.68 (0.46, 1.01)
Pre/peri-menopausal 0.70 (0.43, 1.16) 0.59 (0.33, 1.06) 0.81 (0.50, 1.30) 0.45 (0.24, 0.84)
Post-menopausal 1.10 (0.67, 1.78) 0.62 (0.34, 1.15) 0.68 (0.41, 1.13) 0.99 (0.55, 1.78)
Multinomial logistic regression models predicting odds of breast cancer subtype versus controls. Adjusted for reproductive and clinical characteristics: age, age at
menarche, number of pregnancies, number of births, menopausal status (not included in stratified models), and prior hypertension diagnosis
P-trend based on continuous predictors
aOR per unit SD was modeled as a one-unit increase in standard deviation of the body composition variable from its mean-centered value. These models were
stratified by menopausal status
Bolded values indicate significance at p < .05
Abbreviations: aOR adjusted odds ratio, CI confidence interval, SD standard deviation
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pre-menopausal women. A few studies have evaluated
these associations among Nigerian women, although
most were published over a decade ago prior to the ac-
celerated increase in obesity rates in the region. Specific-
ally, two separate studies observed that a higher waist-
to-hip ratio was associated with significantly increased
risk of BC [17, 18], and three studies showed that height
was associated with significantly increased risk of BC
[16, 17, 23]. Additionally, obesity (defined as BMI ≥ 30)
was found to be associated with increased odds of BC,
although the results were not statistically significant
overall or among pre- or post-menopausal women [16].
For the first time, we present results on the association
between measures of body composition and BC subtypes
compared to controls among West African women. We
found reduced odds of Luminal A, Luminal B, and
HER2-enriched BC among pre/peri-menopausal women,
and reduced odds of TNBC among post-menopausal
women with increased BMI. Prior studies on this topic
are conflicting, and suggest that the associations between
body composition and BC subtypes vary by menopausal
status. A case-control study among Black and White
women in the United States documented a positive asso-
ciation between elevated waist-to-hip ratio and Luminal
A BC among post-menopausal women [25]. Another
analysis, which included studies in the Breast Cancer As-
sociation Consortium, a primarily European population,
found that elevated BMI in younger women was more
strongly associated with hormone receptor positive tu-
mors (Luminal subtypes) [32], and another study from
the United States noted that among post-menopausal
women, BMI was associated with an increased odds of
ER+/PR+ BC [33]. In contrast, a meta-analysis of studies
from the US, Europe, and Asia found that ER+/PR+ tu-
mors were less likely to develop among higher weight
pre-menopausal women, but more likely to develop
among higher weight post-menopausal women [34]. Our
findings are consistent with a prior study that found an
inverse association between BMI and risk of TNBC [35].
However, our findings are inconsistent with other past
studies showing positive associations between obesity
and TNBC [24, 25, 36], most of which were conducted
in study populations from the United States, Europe,
and Asia, and may not be representative of the BC phe-
notypes observed in Nigeria.
Despite the documented inverse association between
BMI and BC risk among pre-menopausal women, the
underlying biological mechanisms remain an active area
of research. For instance, lower levels of progesterone
among pre-menopausal obese women may lead to a
lower risk of BC because progesterone is thought to have
a primarily pro-proliferative role in the adult breast [37].
However, further research is needed to better explain
how excess adiposity contributes to BC risk across
different subtypes. While our findings may suggest lower
BC risk among obese patients relative to lean patients, it
is well-established that BC survival is negatively im-
pacted by obesity [38]. These seemingly paradoxical ob-
servations, dubbed the obesity paradox, may be a
consequence of differences in treatment response among
differently weighted patients [39]. Additionally, bio-
logical mechanisms that explain the higher risk of TNBC
in women of West African descent are not well-
understood. We urge additional research among African
populations to elucidate population-specific risk factors
that may contribute to these outcomes.
Several considerations are relevant for our study.
Given the predominance of the aggressive phenotype
(high grade and TN subtype) of BC in Nigeria, also
reflected in the current study population, it is possible
for cases to have experienced disease associated weight
loss prior to recruitment. It is worth noting that TNBCs
grow quickly and are more likely to be clinically appar-
ent compared with ER+/PR+ cancers, which are more
likely to be detected by screening mammography [40].
The low prevalence of mammogram screening in Nigeria
[41], reflected in our sample with less than 19% of cases
having had a previous mammogram screening, may con-
tribute to the high prevalence of TNBC. However, it is
important to note that studies among African American
women, with similar BC morphological features to Ni-
gerian women [9], have been inconsistent, with some
suggesting positive associations between excess adiposity
and BC risk [42, 43], while others have reported no sig-
nificant associations [44, 45]. The exact relationship be-
tween BMI and BC risk remains conflicting for women
of African descent, indicating a need for further study in
a larger cohort, especially given the context in which BC
disease is distinctly more aggressive [6–8].
There are several strengths and limitations of this
study relevant to the interpretation of these results.
Since covariate data were self-reported at diagnosis, we
cannot exclude the possibility of recall bias. However,
our main exposures of interest, measures of excess adi-
posity, were obtained consistently across study partici-
pants by trained study personnel. Furthermore, because
BMI, height, and weight were recorded at the time of
diagnosis, we are unable to rule out the possibility of re-
verse causality. Additionally, we note the limitation of
relying purely on BMI (height and weight) as a measure
of excess adiposity. Individuals with the same BMI can
have different body fat distributions [46]. Nevertheless,
our study has important strengths, including the use of
histologically confirmed cases of BC from multiple ter-
tiary institutions in Nigeria where the majority of cancer
patients receive treatment, and a vital contribution of di-
verse patient populations to the BC literature. Our study
is the first to characterize the association between
Akinyemiju et al. BMC Cancer         (2021) 21:1051 Page 10 of 13
measures of body composition and BC risk among West
African women by molecular subtype.
In conclusion, measures of body composition were as-
sociated with BC and these associations varied by mo-
lecular subtypes. Larger studies of women of African
descent are needed to better characterize these associa-
tions and enhance population-specific BC prevention
strategies.
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